Search hospitals > Illinois > Chicago
Advocate Illinois Masonic Medical Center
Claim this profileChicago, Illinois 60657
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
106 reported clinical trials
19 medical researchers
Summary
Advocate Illinois Masonic Medical Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Advocate Illinois Masonic Medical Center is involved with conducting 106 clinical trials across 264 conditions. There are 19 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Adam P. Siegel.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
26 reported clinical trials
72 drugs studied
Thomas J. SaphnerAurora Saint Luke's Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
27 reported clinical trials
57 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
14 reported clinical trials
57 drugs studied
Adam P. SiegelAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
10 reported clinical trials
30 drugs studied
Clinical Trials running at Advocate Illinois Masonic Medical Center
Breast Cancer
Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Rectal Cancer
Multiple Myeloma
Bile Duct Cancer
Recurrence
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Advocate Illinois Masonic Medical Center?
Advocate Illinois Masonic Medical Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Advocate Illinois Masonic Medical Center is involved with conducting 106 clinical trials across 264 conditions. There are 19 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Adam P. Siegel.